Researchers report that glial support cells in older retinas become much less likely to convert into new neurons; reducing inflammation with steroids partially restored the regenerative response in mice.
Glia-to-neuron reprogramming that works in young retinas becomes substantially less efficient in aged tissue.
Age-related inflammation (‘inflammaging’) and breakdown of the barrier that keeps immune cells out of nervous tissue are major obstacles to regeneration.
Short-term anti-inflammatory steroid treatment partially rescued the aging retina’s ability to produce new neurons, suggesting the inflammatory environment is a modifiable barrier.
A team led by Levi Todd, PhD, at SUNY Upstate Medical University examined whether methods used to reprogram retinal glia into neurons in young animals still work in aged tissue. The investigators compared several transcription factor–based reprogramming strategies across young and older mouse retinas. Their work was published in Proceedings of the National Academy of Sciences (PNAS).
Across the reprogramming approaches, glia in older retinas were far less efficient at producing neurons than glia in young retinas. The researchers connected that decline to two concrete factors already present in aging tissue: increased inflammation and intrinsic changes to long-lived neural cells.
Inflammation increases with age, a process the team describes by the term inflammaging. The retina and brain normally limit immune entry behind a blood–brain barrier. With age, that barrier weakens, allowing greater immune access. The team says this contributes to a hostile environment for regeneration: immune activity interferes with the ability of glia to change identity and produce neurons.
When researchers treated aging retinas with anti-inflammatory steroids, they saw a partial restoration of the glia's ability to generate neurons. That improvement points to inflammation as a modifiable roadblock. It also highlights the limits of current interventions: steroids broadly suppress immune activity and are not a long-term solution for clinical use.
Context within regenerative research Scientists first showed in 2017 that retinal glia can be induced to make neurons in young mice. Much of the field's optimization since then has focused on young animals. Todd's study is among the first to test those strategies in aged nervous tissue, a critical gap because most neurodegenerative diseases targeted by cell replacement therapies — glaucoma, Alzheimer's, Parkinson's — primarily affect older people.
The lab aims to identify the specific molecules and immune pathways that block regeneration. If researchers can pinpoint those targets, they could develop focused therapies such as monoclonal antibodies that block a single pathway rather than using broad immunosuppression. That would reduce side effects while improving regenerative outcomes. The paper also credits graduate students as the lead contributors to the work.
What this means for patients and researchers The study does not claim immediate clinical solutions, but it changes how researchers should prioritize next experiments. Approaches that work in young tissue will need adaptation for aged environments. Treatments that combine reprogramming factors with targeted control of age-related inflammation are a logical next direction.
Age reduces both the adaptability of retinal cells and the permissiveness of the tissue environment for regeneration. Suppressing inflammation can partially restore regenerative capacity, and identifying the precise inflammatory signals responsible is the next practical step toward usable therapies.
A new study offers fresh hope that some forms of vision loss, once thought to be permanent, might one day be recoverable.
The research community is in the early stages of development of therapies for age-related neurodegeneration based on reprogramming the supporting glial cells of the brain to provoke transformation into neurons. A supply of new neurons can restore lost function, integrating into existing neural circuits. As noted here,
What began as research into a little-known pigment in the eye has led to new insights into nutrition, vision and healthy ageing, as well as a new documentary.
Researchers here provide an initial proof of concept demonstration of a novel foundation for replacing lost visual capacity in cases of retinal degeneration, without addressing the underlying pathology that causes loss of function in photoreceptor cells. Recall that direct stimulation of retinal cells by grid electrode
You already know your chronological age (the amount of years you’ve been alive). But working out your biological age – the “wear and tear happening inside the body at a cellular and molecular level” – isn’t as simple as counting candles on a cake. However, there are clues. Scientists think that how long we can stand on
Randox Health The average person spends 20 years of their life in poor health. Let that sink in. But what if you could avoid that? While there are plenty of zeitgeisty ‘ solutions’ to better health floating around in the ether right now, many of them don’t come with a guarantee. It goes without saying that we’d go out
Loading more related stories...
Open the app view to save this story, compare related coverage, and continue from the same source.